Lisata Therapeutics, Inc. Common Stock
LSTALisata Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for musculoskeletal and degenerative conditions. The company leverages targeted delivery systems to enhance the efficacy of therapeutic agents, aiming to address unmet medical needs in chronic and age-related diseases.
Company News
Kuva Labs Inc. has commenced a tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus contingent value rights worth up to $3.00 per share based on achievement of clinical milestones. The transaction values Lisata at a premium to historical market prices and is expected to close in Q3 2026. Lisata's Board unanimously recommen...
Law firm Brodsky & Smith has initiated investigations into four merger transactions, examining whether the boards of KalVista Pharmaceuticals, Thermon Group Holdings, Sila Realty Trust, and Lisata Therapeutics breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The deals range in value from app...
Monteverde & Associates PC is investigating four merger transactions: Talkspace's sale to Universal Health Services at $5.25/share, Lisata Therapeutics' sale to Kuva Labs at $4.00/share plus contingent value rights, National Storage Affiliates Trust's sale to Public Storage at 0.14 shares per unit, and KalVista Pharmaceuticals' sale to Chiesi Gro...
Law firm Brodsky & Smith announced investigations into four merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Esperion Therapeutics (ARCHIMED acquisition at $3.16/share), Sila Realty Trust (Blue Owl Capital acquisi...
Halper Sadeh LLC, an investor rights law firm, is investigating Sila Realty Trust's $30.38 per share sale to Blue Owl Real Estate Capital affiliates and Lisata Therapeutics' $4.00 per share sale to Kuva Labs. The firm is examining potential securities law violations and breaches of fiduciary duties, seeking to determine if shareholders are receiv...
